divislab glp-1 novo nordisk relation inks Ascendis deal to develop long-acting GLP-1, other metabolic drugs Novo Nordisk: Intense Competition Within – Novo cuts GLP-1 prices 70%,

Distribution Channel Analysis The hospital pharmacies segment grew at a substantial rate, generating a revenue portion of 57.8% as hospitals are key centers for the diagnosis and management of type 2 diabetes and obesity, often initiating treatment with GLP-1 receptor agonists

Scale Our robust architectural and operational capacity allows us to support large-scale obesity and diabetes clinical trials across the globe, currently hosting over 600 active ePRO trials

So far, data from diabetes use is reassuring, but there is not yet decades of information for weight loss use

During the adaptation period, this mismatch contributes to fatigue

Dewi DA et al